These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 15986424)

  • 1. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.
    Zecca L; Berg D; Arzberger T; Ruprecht P; Rausch WD; Musicco M; Tampellini D; Riederer P; Gerlach M; Becker G
    Mov Disord; 2005 Oct; 20(10):1278-85. PubMed ID: 15986424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage.
    Berg D
    J Neural Transm (Vienna); 2006 Jun; 113(6):775-80. PubMed ID: 16755382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.
    Berg D; Roggendorf W; Schröder U; Klein R; Tatschner T; Benz P; Tucha O; Preier M; Lange KW; Reiners K; Gerlach M; Becker G
    Arch Neurol; 2002 Jun; 59(6):999-1005. PubMed ID: 12056937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra.
    Galazka-Friedman J; Bauminger ER; Koziorowski D; Friedman A
    Biochim Biophys Acta; 2004 Mar; 1688(2):130-6. PubMed ID: 14990343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Age on Substantia Nigra Hyper-echogenicity in Parkinson's Disease Patients and Healthy Controls.
    Toomsoo T; Liepelt-Scarfone I; Berg D; Kerner R; Pool AH; Kadastik-Eerme L; Rubanovits I; Asser T; Taba P
    Ultrasound Med Biol; 2019 Jan; 45(1):122-128. PubMed ID: 30482710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transcranial sonography of substantia nigra in patients with Parkinson's disease].
    Miwa H
    Rinsho Shinkeigaku; 2013; 53(11):981-2. PubMed ID: 24291852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease.
    Li DH; Zhang LY; Hu YY; Jiang XF; Zhou HY; Yang Q; Kang WY; Liu J; Chen SD
    Parkinsonism Relat Disord; 2015 Aug; 21(8):923-8. PubMed ID: 26066091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglia activation is related to substantia nigra echogenicity.
    Berg D; Godau J; Riederer P; Gerlach M; Arzberger T
    J Neural Transm (Vienna); 2010 Nov; 117(11):1287-92. PubMed ID: 21057966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes.
    Zecca L; Gallorini M; Schünemann V; Trautwein AX; Gerlach M; Riederer P; Vezzoni P; Tampellini D
    J Neurochem; 2001 Mar; 76(6):1766-73. PubMed ID: 11259494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
    Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
    Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron accumulation in the substantia nigra in rats visualized by ultrasound.
    Berg D; Grote C; Rausch WD; Mäurer M; Wesemann W; Riederer P; Becker G
    Ultrasound Med Biol; 1999 Jul; 25(6):901-4. PubMed ID: 10461717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does ultrasound disclose a vulnerability factor for Parkinson's disease?
    Behnke S; Berg D; Becker G
    J Neurol; 2003 Feb; 250 Suppl 1():I24-7. PubMed ID: 12761631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substantia nigra echogenicity is associated with serum ferritin, gender and iron-related genes in Parkinson's disease.
    Li K; Ge YL; Gu CC; Zhang JR; Jin H; Li J; Cheng XY; Yang YP; Wang F; Zhang YC; Chen J; Mao CJ; Liu CF
    Sci Rep; 2020 May; 10(1):8660. PubMed ID: 32457446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker.
    Berg D; Hochstrasser H; Schweitzer KJ; Riess O
    Neurotox Res; 2006 Jan; 9(1):1-13. PubMed ID: 16464747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.